Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
schizophrenia
Advertisement
MapLight Therapeutics Completes Phase 2 CNS Trials Enrollment
SAN FRANCISCO & BOSTON, May 1, 2026 MapLight Therapeutics, Inc. announced the completion of enrollment in its Phase 2...
Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Axsome Acquires Balipodect to Expand CNS Drug Pipeline
NEW YORK, USA — April 1, 2026 Axsome Therapeutics, Inc. has announced the acquisition of exclusive global rights to...
BioXcel IGALMI sNDA Accepted by FDA for At-Home Use
NEW HAVEN, Conn., USA — April 1, 2026 BioXcel Therapeutics, Inc. announced that the U.S. Food and Drug Administration...
Advertisements
LB Pharma LB-102 Shows Phase 2 Cognitive Benefits in Schizophrenia
New York, USA | March 27, 2026 LB Pharmaceuticals announced new findings from its Phase 2 NOVA-1 clinical trial,...
FDA Approves BYSANTI for Bipolar I and Schizophrenia
WASHINGTON, Feb. 20, 2026 — Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™...
Alto Completes Phase 2 Enrollment for CIAS Drug
MOUNTAIN VIEW, Calif., Feb. 13, 2026 — Alto Neuroscience announced completion of patient enrollment in its Phase 2 proof-of-concept...
NIH Backs RFU Research on Social Deficits in Schizophrenia, ASD
December 18, 2025 | North Chicago, Illinois — Rosalind Franklin University of Medicine and Science has secured $1.73 million...
LB Pharmaceuticals to Present Key Data at Stifel 2025
NEW YORK, November 6, 2025 — LB Pharmaceuticals Inc. (NASDAQ: LBRX), a clinical-stage biopharmaceutical company focused on developing therapies...
Advertisement
